Acute leukaemia following renal transplantation

Milayna Subar, Rasim A. Gucalp, Judith Benstein, Gail Williams, Peter H. Wiernik

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Four renal transplant patients on immunosuppressive therapy who presented with acute myeloid leukaemia are described. In two cases, azathioprine may have played an important role as a cofactor in leukaemogenesis. In a third case, the alkylating agent cyclophosphamide may have contributed. All patients were treated for leukaemia with full doses of cytotoxic chemotherapy and, in each case, a functioning renal allograft was preserved throughout the treatment despite attenuation of immunosuppressive therapy. Three patients achieved complete remission. Of the three, one is surviving at 2 years and two expired during the pancytopenic phase of their treatment with no active leukaemia present, and with intact renal function. As increasing expertise in the held of organ transplantation allows patients to survive longer, such patients' exposure to immunosuppressive and potentially leukaemogenic drugs is prolonged. The risk of secondary neoplasia has been previously documented in this population. Two of the four cases reported here suffered from polycystic kidney disease as their underlying condition. While this report suggests that the leukaemias are related to renal transplantation, we cannot rule out an association with the underlying disease which led to the transplant. This report further suggests that the leukaemia that develops in such patients may respond to standard therapy, and that such treatment does not compromise the transplanted kidney.

Original languageEnglish (US)
Pages (from-to)9-13
Number of pages5
JournalMedical Oncology
Volume13
Issue number1
StatePublished - Mar 1996

Fingerprint

Kidney Transplantation
Leukemia
Immunosuppressive Agents
Kidney
Therapeutics
Transplants
Polycystic Kidney Diseases
Alkylating Agents
Azathioprine
Organ Transplantation
Acute Myeloid Leukemia
Cyclophosphamide
Allografts
Drug Therapy
Pharmaceutical Preparations
Population
Neoplasms

Keywords

  • immunosuppression
  • leukaemia
  • leukaemogenesis
  • transplantation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Subar, M., Gucalp, R. A., Benstein, J., Williams, G., & Wiernik, P. H. (1996). Acute leukaemia following renal transplantation. Medical Oncology, 13(1), 9-13.

Acute leukaemia following renal transplantation. / Subar, Milayna; Gucalp, Rasim A.; Benstein, Judith; Williams, Gail; Wiernik, Peter H.

In: Medical Oncology, Vol. 13, No. 1, 03.1996, p. 9-13.

Research output: Contribution to journalArticle

Subar, M, Gucalp, RA, Benstein, J, Williams, G & Wiernik, PH 1996, 'Acute leukaemia following renal transplantation', Medical Oncology, vol. 13, no. 1, pp. 9-13.
Subar M, Gucalp RA, Benstein J, Williams G, Wiernik PH. Acute leukaemia following renal transplantation. Medical Oncology. 1996 Mar;13(1):9-13.
Subar, Milayna ; Gucalp, Rasim A. ; Benstein, Judith ; Williams, Gail ; Wiernik, Peter H. / Acute leukaemia following renal transplantation. In: Medical Oncology. 1996 ; Vol. 13, No. 1. pp. 9-13.
@article{8e767acadd3746448f6e2bbf49df2324,
title = "Acute leukaemia following renal transplantation",
abstract = "Four renal transplant patients on immunosuppressive therapy who presented with acute myeloid leukaemia are described. In two cases, azathioprine may have played an important role as a cofactor in leukaemogenesis. In a third case, the alkylating agent cyclophosphamide may have contributed. All patients were treated for leukaemia with full doses of cytotoxic chemotherapy and, in each case, a functioning renal allograft was preserved throughout the treatment despite attenuation of immunosuppressive therapy. Three patients achieved complete remission. Of the three, one is surviving at 2 years and two expired during the pancytopenic phase of their treatment with no active leukaemia present, and with intact renal function. As increasing expertise in the held of organ transplantation allows patients to survive longer, such patients' exposure to immunosuppressive and potentially leukaemogenic drugs is prolonged. The risk of secondary neoplasia has been previously documented in this population. Two of the four cases reported here suffered from polycystic kidney disease as their underlying condition. While this report suggests that the leukaemias are related to renal transplantation, we cannot rule out an association with the underlying disease which led to the transplant. This report further suggests that the leukaemia that develops in such patients may respond to standard therapy, and that such treatment does not compromise the transplanted kidney.",
keywords = "immunosuppression, leukaemia, leukaemogenesis, transplantation",
author = "Milayna Subar and Gucalp, {Rasim A.} and Judith Benstein and Gail Williams and Wiernik, {Peter H.}",
year = "1996",
month = "3",
language = "English (US)",
volume = "13",
pages = "9--13",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Acute leukaemia following renal transplantation

AU - Subar, Milayna

AU - Gucalp, Rasim A.

AU - Benstein, Judith

AU - Williams, Gail

AU - Wiernik, Peter H.

PY - 1996/3

Y1 - 1996/3

N2 - Four renal transplant patients on immunosuppressive therapy who presented with acute myeloid leukaemia are described. In two cases, azathioprine may have played an important role as a cofactor in leukaemogenesis. In a third case, the alkylating agent cyclophosphamide may have contributed. All patients were treated for leukaemia with full doses of cytotoxic chemotherapy and, in each case, a functioning renal allograft was preserved throughout the treatment despite attenuation of immunosuppressive therapy. Three patients achieved complete remission. Of the three, one is surviving at 2 years and two expired during the pancytopenic phase of their treatment with no active leukaemia present, and with intact renal function. As increasing expertise in the held of organ transplantation allows patients to survive longer, such patients' exposure to immunosuppressive and potentially leukaemogenic drugs is prolonged. The risk of secondary neoplasia has been previously documented in this population. Two of the four cases reported here suffered from polycystic kidney disease as their underlying condition. While this report suggests that the leukaemias are related to renal transplantation, we cannot rule out an association with the underlying disease which led to the transplant. This report further suggests that the leukaemia that develops in such patients may respond to standard therapy, and that such treatment does not compromise the transplanted kidney.

AB - Four renal transplant patients on immunosuppressive therapy who presented with acute myeloid leukaemia are described. In two cases, azathioprine may have played an important role as a cofactor in leukaemogenesis. In a third case, the alkylating agent cyclophosphamide may have contributed. All patients were treated for leukaemia with full doses of cytotoxic chemotherapy and, in each case, a functioning renal allograft was preserved throughout the treatment despite attenuation of immunosuppressive therapy. Three patients achieved complete remission. Of the three, one is surviving at 2 years and two expired during the pancytopenic phase of their treatment with no active leukaemia present, and with intact renal function. As increasing expertise in the held of organ transplantation allows patients to survive longer, such patients' exposure to immunosuppressive and potentially leukaemogenic drugs is prolonged. The risk of secondary neoplasia has been previously documented in this population. Two of the four cases reported here suffered from polycystic kidney disease as their underlying condition. While this report suggests that the leukaemias are related to renal transplantation, we cannot rule out an association with the underlying disease which led to the transplant. This report further suggests that the leukaemia that develops in such patients may respond to standard therapy, and that such treatment does not compromise the transplanted kidney.

KW - immunosuppression

KW - leukaemia

KW - leukaemogenesis

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=0029817066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029817066&partnerID=8YFLogxK

M3 - Article

C2 - 8869934

AN - SCOPUS:0029817066

VL - 13

SP - 9

EP - 13

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 0340-7004

IS - 1

ER -